Valuation : Arcus Biosciences, Inc.

Market Cap 3.9B 3.36B 3.15B 2.87B 5.41B 372B 5.43B 37.34B 14.57B 188B 14.62B 14.31B 623B P/E 2026 *
-8.55x
P/E 2027 * -8.49x
Enterprise Value 3.45B 2.98B 2.79B 2.55B 4.8B 330B 4.81B 33.11B 12.92B 167B 12.97B 12.69B 553B EV / Sales 2026 *
43.9x
EV / Sales 2027 * 72.8x
Free-Float
71.2%
Yield 2026 *
-
Yield 2027 * -
1 day-4.51%
1 week-3.72%
Current month+3.62%
1 month+7.99%
3 months+19.32%
6 months+22.01%
Current year+22.58%
1 week 29.06
Extreme 29.06
31.58
1 month 26.19
Extreme 26.19
31.58
Current year 18.52
Extreme 18.515
31.74
1 year 10.4
Extreme 10.395
31.74
3 years 6.5
Extreme 6.5
31.74
5 years 6.5
Extreme 6.5
49.1
10 years 6.3
Extreme 6.3
49.1
Manager TitleAgeSince
President 68 01/05/2015
Chief Executive Officer 67 01/05/2015
Director of Finance/CFO 53 01/08/2020
Director TitleAgeSince
Chairman 67 01/12/2017
Director/Board Member 65 18/09/2017
Director/Board Member 72 01/05/2015
Date Insider Type Main position Quantity % Market Cap.
21/8/26 Fiscal year

Controller/Auditor

8,481 0.0067%
10/7/26 Sell

Founder

-20,067 0.0160%
11/6/26 Free

Director

22,600 0.0180%
Change 5-day change 1-year change 3-year change Capi.($)
-4.51%-3.72%+175.31%+34.24% 3.9B
-0.78%-0.34%+1.99%+23.35% 51.14B
-6.00%-0.75%+442.41%+544.39% 47.4B
-0.24%+0.74%+38.69%+18.02% 43.19B
-1.55%-2.07%+23.08%+81.47% 42.35B
-0.31%-1.75%+17.23%+52.37% 33.23B
-1.79%-3.24%+27.00%+129.56% 17.07B
-0.58%-2.12% - - 16.38B
-0.88%-0.63%+11.05%+29.54% 14.76B
-1.66%-1.25%+78.59%+46.66% 14.15B
Average -1.79%+0.99%+90.60%+106.62% 28.36B
Weighted average by Cap. -1.71%+1.15%+99.98%+136.27%

Financials

2026 *2027 *
Net sales 78.61M 67.74M 63.51M 57.98M 109M 7.51B 110M 753M 294M 3.79B 295M 289M 12.58B 52.08M 44.88M 42.08M 38.41M 72.36M 4.98B 72.59M 499M 195M 2.51B 196M 191M 8.33B
Net income -451M -389M -364M -333M -627M -43.1B -629M -4.32B -1.69B -21.76B -1.69B -1.66B -72.15B -451M -389M -365M -333M -627M -43.13B -629M -4.33B -1.69B -21.77B -1.69B -1.66B -72.19B
Net Debt -441M -380M -356M -325M -612M -42.11B -614M -4.22B -1.65B -21.26B -1.65B -1.62B -70.49B -102M -88.03M -82.54M -75.35M -142M -9.76B -142M -979M -382M -4.93B -384M -375M -16.34B
Logo Arcus Biosciences, Inc.
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company has a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.
Employees
601
Date Price Change Volume
29/08/26 US$29.21 -4.51% 1,086,192
27/08/26 US$30.59 -0.55% 806,056
26/08/26 US$30.76 -2.57% 685,582
25/08/26 US$31.57 +4.81% 655,704
24/08/26 US$30.12 -0.73% 1,296,258
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
30.59USD
Average target price
38.33USD
Spread / Average Target
+25.31%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RCUS Stock